| |
|
|
|
Xtalks — The Life Science Community™, Online webinar
2026-06-30
Attendees will learn how to: - Navigate US payer expectations for biomarker-driven therapies
- Address evidence gaps in small, targeted populations and validate endpoints
- Use real-world data and external comparators to demonstrate value
- Build integrated, cross-functional evidence strategies that support reimbursement and access
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks — The Life Science Community™ |
|
|
Invited Speakers:
|
|
Adam Petrich | MD | Vice President, Oncology, Medical Science and Strategy | Thermo Fisher Scientific Dr. Petrich brings more than 20 years of experience in oncology clinical development across pharmaceutical and biotech settings. He leads strategic clinical trial design and execution with a focus on biospecimen-driven precision oncology, including the integration of biomarker strategies and AI-enabled approaches to improve patient selection and clinical outcomes. Dr. Petrich has guided multiple therapies from early development through regulatory approval and launch and is board-certified in oncology, hematology and internal medicine. Priya Jain | MS, MBA | Executive Director, PPD Evidera Health Economics & Market Access | Thermo Fisher Scientific Priya brings more than 17 years of global biotech and pharmaceutical experience with deep expertise in market access and product commercialization. She partners with clients to develop integrated strategies spanning pricing, payer evidence, patient access and reimbursement, helping ensure therapies demonstrate clear value across stakeholders and achieve commercial success. Priya has extensive experience across therapeutic areas, including oncology, immunology and rare diseases, and is known for aligning evidence generation and market access strategy to support optimal patient access. John Hamlet | | Executive Director, Neuroscience Pillar Head | Thermo Fisher Scientific John brings more than 30 years of experience in the clinical research and pharmaceutical industry. He leads global neuroscience drug development programs across complex indications, overseeing study execution, operational strategy and data integrity to ensure consistent, high-quality delivery. John also champions advanced scientific surveillance approaches to enhance signal detection, mitigate placebo response and strengthen trial quality while driving operational excellence in neurologic drug development. Amanda Pulfer | BA | Executive Director, Integrated Solutions, RWE, PPD Evidera Real-World Data & Scientific Solutions | Thermo Fisher Scientific Amanda leads the development of integrated real-world data (RWD) and real-world evidence (RWE) solutions, designing innovative studies that balance client objectives with scientific rigor. With more than 25 years of experience, she partners with biopharma organizations to generate impactful evidence across the product lifecycle, supporting decision-making from development through commercialization. Amanda brings broad therapeutic expertise, including oncology, rare diseases and immunology, and a strong focus on translating complex data into actionable insights. Elizabeth Dansie Bacci | PhD | Senior Research Scientist, PPD Evidera Patient-Centered Research | Thermo Fisher Scientific Dr. Dansie Bacci brings more than 15 years of experience in outcomes research across a wide range of therapeutic areas, including rare disease, neurology and chronic conditions. She specializes in the development, validation and implementation of patient-reported outcome measures to support clinical trials and real-world studies, with a focus on ensuring endpoints are meaningful to patients, clinicians and payers. Dr. Dansie Bacci also brings deep expertise in study design, psychometric evaluation and advanced analytics, helping translate patient-centered data into evidence that strengthens clinical and value-based decision-making.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2026-06-30
|
|
|
|
|
|
|
|
Registration:
|
|
Register here
|
|
|
E-mail:
|
|
clientservices@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|